The role of chondroprotectors in the pharmacological treatment of osteoarthritis
https://doi.org/10.21518/2079-701X-2019-6-100-109
Abstract
The article is devoted to third-generation slow-modifying chondroprotective drug therapy including Alflutop. The evidence-based medicine showed and substantiated in vitro effect of the drug on the pathogenetic processes in the cartilage tissue, its promotion of the inflammation regression in the musculoskeletal system. The authors present a series of clinical studies of top osteoarthritis doctors, which showed that Alflutop had an anti-inflammatory, chondroprotective, analgesic effect, and that the administration of the drug allowed patients to reduce the doses of NSAIDs, and it could be used in patients with comorbid diseases.
About the Authors
L. K. Peshekhonova
Federal State Budgetary Education Institution of Higher Education «Burdenko Voronezh State Medical University» of the Ministry of Health of the Russian Federation;
Non-state Health Care Facility «Road Clinical Hospital at the station Voronezh-1 of JSC» Russian Railways»
Russian Federation
Russian Federation
Peshekhonova Lyudmila Konstantinovna – Dr. of Sci. (Med.), Professor of Chair for Occupational Medicine, Federal State Budgetary Educational Institution of Higher Education «Burdenko Voronezh State Medical University» of the Ministry of Health of the Russian Federation, Head of Rheumatology Department, Non-state Health Care Facility «Road Clinical Hospital at the station Voronezh-1 of JSC» Russian Railways»
394036, Voronezh, Studencheskaya St., 10, 394024, Voronezh, per. Zdorovia, 2
P. A. Krasyukov
Federal State Budgetary Education Institution of Higher Education «Burdenko Voronezh State Medical University» of the Ministry of Health of the Russian Federation;
Non-state Health Care Facility «Road Clinical Hospital at the station Voronezh-1 of JSC» Russian Railways»
Russian Federation
Russian Federation
Krasyukov Pavel Aleksandrovich – Cand. of Sci. (Med.), Assistant Professor of Chair for Clinical Pharmacology, Federal State Budgetary Educational Institution of Higher Education «Burdenko Voronezh State Medical University» of the Ministry of Health of the Russian Federation, Resident Physician of Rheumatology Department, Non-state Health Care Facility «Road Clinical Hospital at the station Voronezh-1 of JSC» Russian Railways»
394036, Voronezh, Studencheskaya St., 10, 394024, Voronezh, per. Zdorovia, 2
References
1. Groppa L., Mynzatu I., Karasawa M., et al. The efficacy of Alflutop in patients with deforming osteoarthrosis. Klinicheskaya Revmatologia. 1995;3:20-22. (In Russ).
2. Lukina G.V., Sigidin Ya.A. Chondroprotector Alflutop in the treatment of osteoarthritis. Nauchno-Prakticheskaya Revmatologia. 2001;2:51-53. (In Russ).
3. Korshunov N.I. Chondroprotective therapy of patients with osteoarthritis. Pharmateca. 2008;12(66):71-74. (In Russ).
4. Rachin A.P. Evidence-based pharmacoanalysis of osteoarthritis treatment. Pharmateca. 2007;19:81-86. (In Russ).
5. Лила А.М. Локальная терапия заболеваний суставов. РМЖ. 2005;13(8):535-539. [Lila A.M. Local therapy of joint diseases. RMJ. 2005;13(8):535-539.] (In Russ).
6. Chichasova N.V., Imametdinova G.R., Shevchenko O.V. Injection therapy for osteoarthritis. Kachestvo Zhizni. Meditsina. Bolezni Kostno-Myshechnoy Sistemy. 2003;3:69-72 (In Russ).
7. Lukina G.V., Sigidin Ya.A., Chichasova N.V., Mach E.V. Report on the use of chondroprotector Alflutop in the treatment of osteoarthritis. State Institute of Rheumatology, Russian Academy of Medical Sciences, 2003 Collected papers on Alflutop materials for 2001–2003.1. Rompharm company. 119 p. (In Russ).
8. Zborovsky A.B., Mozgovaya E.E. Alflutop: experience of longcontinued clinical use. Pharmateca. 2006;19:35-40. (In Russ).
9. http://www.chondro.jp/english/04senmon/index.html.
10. Salikhov I.G., Volkova E.R., Yakupova S.P. Periarticular application of chondroprotectors in patients with gonarthrosis and signs of tendon-ligament apparatus injury. Consilium Medicum. 2006;8(2):59-61. (In Russ).
11. Pepa G.D. and Brandi M.L. Microelements for bone boost: the last but not the least. Clin Cases Miner Bone Metab. 2016 SepDec;13(3):181-185.
12. Biochemistry guide. Under the editorship of E.S. Severin, 2008. (In Russ.)
13. Olariu L., Dumitriu B., Buse E., ROSOIU N. The in vitro effect of Alflutop® product on some extracellular signaling factors involved in the osteoarticular pathology inflammation. Academy of Romanian Scientists Annals Series on Biological Sciences. 2015;4(2):7-18.
14. Lukina G.V., Sigidin Ya.A. Chondroprotector Alflutop in the treatment of osteoarthritis. Collected articles «Evidence-Based Medicine. Research dossier: The results of clinical studies in real clinical practice for 20 years of use of Alflutop in 1995–2014.» 2015 (In Russ).
15. Risbud M.V. and Shapiro I.M. Role of cytokines in intervertebral disc degeneration: pain and disc content. Not. Rev. Rheumatol. 2014;10:44-56.
16. Alekseeva L.I., et al. A multicenter blind, randomized, placebo-controlled study of the symptom- and structural-modifying effect of Alflutop in patients with knee joint osteoarthritis. Communication 1: assessment of the symptom-modifying effect of the drug. Nauchno-Prakticheskaya Revmatologia. 2013;5:532-538. (In Russ).
17. Alekseeva L.I., et al. A multicenter blind, randomized, placebo-controlled study of the symptom- and structuralmodifying effect of Alflutop in patients with knee joint osteoarthritis. Communication 2: assessment of the structural-modifying effect of the drug. Nauchno-Prakticheskaya Revmatologia. 2014;52(2):174-177. (In Russ).
18. Korshunov N.I., Marasayev V.V., Baranova E.Y., et al. The role of inflammation and the assessment of Alflutop’s chondroprotective effect in patients with osteoarthritis based on magnetic resonance imaging findings in the knee joint. RMJ. 2003;23:1320. (In Russ).
19. Svetlova M.S. The use of Alflutop and glucosamine hydrochloride in the treatment of patients with osteoarthritis: extended abstract of Cand. Sci. (Med.) Dissertation. Yaroslavl, 2003, 25 p. (In Russ).
20. Svetlova M.S., Ignatiev V.K. Use of Alflutop in the treatment of patients with osteoarthritis. Klinicheskaya Meditsina. 2004;6 (In Russ).
21. Peshekhonov L.K., Krasyukov P.A., Peshekhonov D.V. Assessment of the role of Alflutop in the treatment of osteoarthrosis: indications, clinical efficacy, tolerance and impact on the quality of life. Meditsinsky Sovet. Revmatologia. 2016;11. (In Russ).
22. Khitrov N.A., Local injection therapy for para-articular tissues injury. Khirurgia. 2017;11. (In Russ).
23. Drozdov V.N., Kolomiets E.V. Use of Alflutop in patients with gastropathy that developed during the NSAIDs therapy. Pharmateca. 2005;20. (In Russ).
24. Lee K.M. et al. Risk factors for osteoarthritis and contributing factors to current arthritis pain in South Korean older adults. Yonsei Med J. 2015;56:124-31.
25. Management of patients with osteoarthritis and comorbidity in general medical practice. M.: RNMOT, 2016. (In Russ).
Review
For citations:
Peshekhonova LK, Krasyukov PA. The role of chondroprotectors in the pharmacological treatment of osteoarthritis. Meditsinskiy sovet = Medical Council. 2019;(6):100-109. (In Russ.) https://doi.org/10.21518/2079-701X-2019-6-100-109
Views:
804
Email this article 